# INNOVATE Corp.: Form 10-Q for the period ended Sep 30, 2024

- Company: [INNOVATE Corp.](/companies/vate.md) (CIK 1006837)
- Form: 10-Q
- Filed: 2024-11-06
- Accepted by EDGAR: Nov 6, 2024, 16:07 ET
- Period: 2024-09-30
- Accession: 0001006837-24-000155
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006837/000100683724000155/vate-20240930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006837/000100683724000155/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-30 | $242.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-01-01 to 2024-09-30 | $870.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-07-01 to 2024-09-30 | $194.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2024-01-01 to 2024-09-30 | $708.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2024-07-01 to 2024-09-30 | $48.2m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-01-01 to 2024-09-30 | $162.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2024-07-01 to 2024-09-30 | $37.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2024-01-01 to 2024-09-30 | $119.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-07-01 to 2024-09-30 | $5.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-30 | $37.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-07-01 to 2024-09-30 | $3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-30 | $3.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | −$15.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | −$18.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | −$1.18 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | −$1.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | −$1.18 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | −$1.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 12,966,322 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 9,928,679 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | −$32.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2024-07-01 to 2024-09-30 | $3.1m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-30 | $11.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2024-01-01 to 2024-09-30 | $900.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2024-09-30 | $51.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $399.9m | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $897.2m | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $468.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-30 | $1.02bn | us-gaap:Liabilities |
| Current portion of debt | at 2024-09-30 | $189.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-09-30 | −$163.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 121,332 characters.

You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated annual audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 6, 2024 (the "2023 Annual Report") and the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section in our 2023 Annual Report as well as the section below entitled "Special Note Regarding Forward-Looking Statements" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless the context otherwise requires, in this Quarterly Report on Form 10-Q, "INNOVATE" means INNOVATE Corp. and the "Company," "we" and "our" mean INNOVATE together with its consolidated subsidiaries. "U.S. GAAP" means accounting principles accepted in the United States of America.

### Our Business and Our Operations

We are a diversified holding company with principal operations conducted through three operating platforms or reportable segments: Infrastructure ("DBMG"), Life Sciences ("Pansend"), and Spectrum, plus our Other segment, which includes businesses that do not meet the separately reportable segment thresholds.

For additional information on our business, refer to Note 1. Organization and Business to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Cyclical Patterns

Our segments' operations can be highly cyclical. Our volume of business in our Infrastructure segment may be adversely affected by declines or delays in projects, which may vary by geographic region. Project schedules, particularly in connection with large, complex, and longer-term projects can also create fluctuations in the services provided, which may adversely affect us in any given period.

For example, in connection with larger, more complicated projects, the timing of obtaining permits and other approvals may be delayed, and we may need to maintain a portion of our workforce and equipment in an underutilized capacity to ensure we are strategically positioned to deliver on such projects when they move forward.

Examples of other items that may cause our results or demand for our services to fluctuate materially from quarter to quarter include: weather or project site conditions; financial condition of our customers and their access to capital; margins of projects performed during any particular period; rising interest rates and inflation; and economic, political and market conditions on a regional, national or global scale.

Accordingly, our operating results in any particular period may not be indicative of the results that can be expected for any other period.

### Recent Developments

We continually evaluate strategic and business alternatives within our operating segments, which may include the following: operating, growing or acquiring additional assets or businesses related to current or historical operations; or winding down or selling our existing operations. In the longer-term, we may evaluate opportunities to acquire assets or businesses unrelated to our current or historical operations. In the event we were to enter into a strategic transaction to sell any of our existing operations, our intention is to use available proceeds from such transaction to address our capital structure at our Non-Operating Corporate and Spectrum segments.

In 2024, including subsequent to the third quarter end, as part of our strategic process, we engaged in several transactions that had or will have an effect on the results of operations and financial condition of our business and individual segments.

### Reverse Stock Split

On August 8, 2024, the Company effected a 1-for-10 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”) following stockholder approval. The Reverse Stock Split became effective at 5:00 p.m. Eastern Standard Time. The Reverse Stock Split was implemented for the primary purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company’s common stock on the NYSE. As a result of the Reverse Stock Split, every ten shares of the Company’s common stock issued and outstanding were automatically reclassified and changed into one new share of the Company’s common stock, with whole shares issued for fractional shares. Proportionate adjustments were made to the exercise prices and the number of shares underlying the Company’s outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company’s equity incentive plans and conversion of the Company’s outstanding convertible securities. The common stock issued pursuant to the Reverse Stock Split will remain fully paid and non-assessable. The Reverse Stock Split did not change the $0.001 par value per share of the common stock or the authorized number of shares of common stock or preferred stock. As a result of the Reverse Stock Split, the number of outstanding common shares was reduced from 130,529,931 to 13,166,057, inclusive of an additional 113,064 incremental whole shares issued for fractional shares. Unless noted, all common shares and per share amounts of common stock, options and restricted stock and any associated debt or preferred stock conversion rates contained in the historical periods presented within this Management’s Discussion and Analysis of Financial Condition and Results of Operations and within the unaudited Condensed Consolidated Financial Statements have been retroactively adjusted to reflect the one-for-ten Reverse Stock Split.

### Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a $19.0 million rights offering ("Rights Offering") for its common stock. Pursuant to the Rights Offering, the Company distributed to each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), transferable subscription rights to purchase 0.2858 shares of the Company’s common stock at a price of $0.70 per whole share (on a pre Reverse Stock Split basis).

Per the concurrent investment agreement entered into with Lancer Capital (the "Investment Agreement"), the Rights Offering was backstopped by Lancer Capital, an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. Due to limitations on the common stock that can be issued to Lancer Capital under the rules of the New York Stock Exchange ("NYSE"), in lieu of exercising its subscription rights, pursuant to the Investment Agreement, Lancer Capital would purchase up to $19.0 million of the Company’s newly issued Series C Non-Voting Participating Convertible Preferred Stock (the “Series C Preferred Stock”), for an issue price of $1,000 per share. In connection with the backstop commitment, and as a result of limitations in the amount common equity that can be raised under the Company’s effective shelf registration statement on Form S-3, Lancer Capital also agreed to purchase an additional $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement") which was to close concurrently with the settlement of the Rights Offering. Lancer Capital did not receive any compensation or other consideration for entering into or consummating the Investment Agreement.

As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock (5,306,105 shares of common stock on a pre Reverse Stock Split basis) for $3.7 million. Based on the number of shares of common stock actually sold upon exercise of the rights to third party investors, there were no excess shares of Series C Preferred Stock purchased by Lancer Capital under the equity advance that the Company was required to redeem, and Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the backstop commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which have been capitalized into Additional paid in capital ("APIC"). INNOVATE has been utilizing and expects to continue to use the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and working capital. In addition, as a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Unsecured Note, and consequently, on April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note.

Under the rules of the NYSE, because the shares purchased by Lancer Capital were greater than 20% of the Company's common stock outstanding before the issuance of the Series C Preferred Stock, those shares of Series C Preferred Stock were not allowed to be converted until stockholder approval of such issuance was obtained. On June 18, 2024, the Company held its annual shareholder meeting where Company's shareholder's approved the conversion of the Series C Preferred Stock into common stock. As a result, approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock (44,693,895 shares of common stock on a pre Reverse Stock Split basis).

The Company waived its Tax Benefits Preservation Plan to permit persons exercising rights to acquire 4.9% or more of the outstanding common stock upon the exercise thereof without becoming an Acquiring Person (as defined in the Tax Benefits Preservation Plan).

INNOVATE has used and expects to continue to use the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and for working capital. As a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Unsecured Note, in the amount of the greater of $3.0 million or 12.5% of the net proceeds. On April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note.

### Stockholders’ Rights Agreement - Tax Benefits Preservation Plan

On May 6, 2024, the Company terminated its Tax Benefits Preservation Plan entered into on April 1, 2023 (the “2023 Preservation Plan”) because the Company’s Board of Directors determined that the 2023 Preservation Plan was no longer necessary or desirable for the preservation of the Company’s ability to use its tax net operating losses and other certain tax assets. In connection with the termination of the 2023 Preservation Plan, the Company has taken routine actions to deregister the related preferred stock purchase rights under the Securities Exchange Act of 1934, and to delist the preferred stock purchase rights from the NYSE. These actions were administrative in nature and had no effect on the Company’s common stock, which will continue to be listed on the NYSE.

### Amendment to Second and Restated 2014 Omnibus Equity Award Plan and Interim CEO Equity Awards

As of September 30, 2024, prior to adoption by the Board of Directors (the "Board"), there were a total of 101,943 shares of common stock available for future award under the Company's Second Amended and Restated 2014 Omnibus Equity Award Plan ("Second A&R 2014 Plan"). On September 30, 2024, the Board adopted, subject to stockholder approval, an amendment to the Second A&R 2014 Plan to increase the number of shares of the Company's common stock, par value $0.001 per share, available for issuance thereunder to 1,300,000 (the “Plan Amendment”). The Plan Amendment was approved by holders of a majority in voting power on October 4, 2024, by written consent in lieu of a special meeting, to be effective as of October 29, 2024.

Subsequent to quarter end, on October 29, 2024, when the Plan Amendment became effective, the following awards which were previously awarded to the Company's Interim CEO subject to stockholder approval of the Plan Amendment to increase the number of shares of common stock available thereunder to satisfy the settlement of the grant ("Share Approval Condition") became effective: (i) 95,322 of restricted stock unit awards ("RSU's"), which were awarded on October 11, 2023; (ii) 100,000 option awards with a strike price of $25.00 (as retroactively adjusted for the Reverse Stock Split in 2024) and an expiration date of September 15, 2033, which were awarded on September 15, 2023; (iii) 142,857 of RSUs, which were awarded on August 19, 2024; and (iv) 100,000 option awards with a strike price of $4.22 and an expiration date of September 15, 2034, which were awarded on September 15, 2024.

### Debt Obligations and Financing

In addition to the Rights Offering and Concurrent Private Placement at the Non-Operating Corporate segment discussed above, during 2024 thus far, we have refinanced some of our debt and obtained new capital financing at the subsidiary level. This financing helped us provide needed capital for our operations and the operations of our subsidiaries.

#### Infrastructure

On June 28, 2024, DBM and UMB entered into the Third Amendment to the UMB Credit Agreement. The amendment adds an incremental separate term loan of $25.0 million to the existing credit facility, with the same interest rate as the Revolving Line with UMB and the same maturity date as the initial $76.3 million UMB term loan.

During the nine months ended September 30, 2024, DBMG made $5.0 million in scheduled payments on the 4.0% note that was payable to Banker Steel's former owner. The 4.0% note matured on March 31, 2024, and was fully redeemed on April 2, 2024.

#### Life Sciences

R2 Technologies had various short-term notes with Lancer Capital, which expired on January 31, 2024, and, effective January 31, 2024, a new 20% note with an aggregate original principal amount of $20.0 million was issued, which was comprised of all prior outstanding principal amounts and unpaid accrued interest of $2.6 million which was capitalized into the new principal balance. Interest on the note accrued at 20% per annum and was payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest was capitalized monthly into the principal balance. The 20% $20.0 million note also included an exit fee of 10.5% of the principal amount being repaid if repaid anytime from April 1, 2024 through April 30, 2024. The original maturity date of the 20% $20.0 million note was April 30, 2024, or within five business days of the date on which R2 Technologies receives an aggregate $20.0 million from the consummation of a debt or equity financing or has a change in control, as defined in the agreement, with an optional prepayment of the entire then-outstanding and unpaid principal and accrued interest upon five-days written notice to Lancer Capital. Effective May 17, 2024, the maturity date of the note was extended to December 31, 2024, and the exit fees were amended.

The initial exit fee, as amended, as of September 30, 2024 was equal to 11.39% of the principal amount being repaid and continues to increase by 0.17% each month thereafter until maturity. Effective July 31, 2024, an additional exit fee of $1.0 million was incurred under the amendment, which increases by $1.0 million each month until the end of November 2024. If unpaid prior to maturity, the total exit fees payable will be $7.9 million. The exit fees are being amortized over the term of the note using the effective interest rate method and are included in interest expense. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. As of September 30, 2024, total accrued exit fees were $5.6 million and were included within Accrued liabilities on the Condensed Consolidated Balance Sheet.

Refer to Note 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

On June 20, 2024, Pansend closed on a new Series D Preferred Stock ("Series D") investment in R2 Technologies. As part of the transaction, R2 Technologies converted $15.5 million of intercompany notes with Pansend into Series D shares. The total converted amount of $15.5 million consisted of $13.7 million in principal amount and $1.8 million of accrued interest owed to Pansend, which were eliminated in consolidation. Pansend also invested an additional $5.8 million of cash into R2 Technologies in exchange for $5.8 million of Series D shares for a total new additional investment of $21.3 million in convertible participating preferred stock, which increased Pansend's ownership in R2 Technologies to 81.4% as compared to 56.8% prior to the transaction. Pansend's ownership in R2 Technologies was 81.4% and 56.6%, as of September 30, 2024 and December 31, 2023, respectively. Refer to Note 15. Equity and Temporary Equity, which is incorporated herein by reference, for additional information on R2 Technology's convertible preferred stock.

#### Non-Operating Corporate

On May 6, 2024, we extended the maturity date of our Revolving Line of Credit with MSD from March 16, 2025 to May 16, 2025.

During the three and nine months ended September 30, 2024, we repurchased $2.9 million principal amount of its 2026 Convertible Notes at a market discount for $1.1 million, which is inclusive of accrued interest of $0.1 million, and recognized a $1.9 million gain on debt repurchase within Other income, net in the Condensed Consolidated Statement of Operations.

### Equity Method Investments

During the nine months ended September 30, 2024, MediBeacon issued an aggregate $2.3 million of 12% convertible notes payable to Pansend, increasing the total outstanding principal due Pansend to $12.0 million.

As a result of these note issuances by MediBeacon during the nine months ended September 30, 2024, Pansend recognized $2.3 million of equity method losses which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero. As of September 30, 2024, Pansend's carrying amount of its investment in MediBeacon remains at zero, inclusive of the $12.0 million in outstanding notes which have been offset against recognized losses, and has cumulative unrecognized equity method losses relating to MediBeacon of $10.9 million.

### Financial Presentation Background

In the below section within this Management’s Discussion and Analysis of Financial Condition and Results of Operations, we compare, pursuant to U.S. GAAP and SEC disclosure rules, the Company’s results of operations for the three and nine months ended September 30, 2024, as compared to the three and nine months ended September 30, 2023.

### Results of Operations

The following table summarizes our results of operations (in millions):

| Revenue | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Infrastructure | $232.8 | $369.3 | $(136.5) | $845.9 | $1,043.4 | $(197.5) |
| Life Sciences | 3.0 | 0.6 | 2.4 | 5.7 | 1.8 | 3.9 |
| Spectrum | 6.4 | 5.4 | 1.0 | 18.9 | 16.8 | 2.1 |
| Total revenue | $242.2 | $375.3 | $(133.1) | $870.5 | $1,062.0 | $(191.5) |
| Income (loss) from operations |  |  |  |  |  |  |
| Infrastructure | $12.3 | $20.9 | $(8.6) | $57.1 | $41.9 | $15.2 |
| Life Sciences | (3.3) | (3.3) | — | (10.5) | (11.6) | 1.1 |
| Spectrum | (0.1) | (2.1) | 2.0 | 0.2 | (3.2) | 3.4 |
| Other | — | — | — | — | (1.9) | 1.9 |
| Non-Operating Corporate | (3.0) | (4.8) | 1.8 | (9.3) | (12.7) | 3.4 |
| Total income from operations | $5.9 | $10.7 | $(4.8) | $37.5 | $12.5 | $25.0 |
| Interest expense | (21.2) | (17.1) | (4.1) | (54.9) | (49.0) | (5.9) |
| Loss from equity investees | — | (1.5) | 1.5 | (2.3) | (5.8) | 3.5 |
| Other income, net | 2.2 | 0.4 | 1.8 | 1.2 | 17.2 | (16.0) |
| Loss from operations before income taxes | $(13.1) | $(7.5) | $(5.6) | $(18.5) | $(25.1) | $6.6 |
| Income tax expense | (3.1) | (1.1) | (2.0) | (3.9) | (3.2) | (0.7) |
| Net loss | $(16.2) | $(8.6) | $(7.6) | $(22.4) | $(28.3) | $5.9 |
| Net loss attributable to non-controlling interests and redeemable non-controlling interests | 1.2 | 1.6 | (0.4) | 4.4 | 2.4 | 2.0 |
| Net loss attributable to INNOVATE Corp. | $(15.0) | $(7.0) | $(8.0) | $(18.0) | $(25.9) | $7.9 |
| Less: Preferred dividends | 0.3 | 0.3 | — | 0.9 | 2.1 | (1.2) |
| Net loss attributable to common stockholders and participating preferred stockholders | $(15.3) | $(7.3) | $(8.0) | $(18.9) | $(28.0) | $9.1 |

*Revenue*: Revenue for the three months ended September 30, 2024 decreased $133.1 million to $242.2 million from $375.3 million for the three months ended September 30, 2023. Revenue for the nine months ended September 30, 2024 decreased $191.5 million to $870.5 million from $1,062.0 million for the nine months ended September 30, 2023. The decreases were driven by our Infrastructure segment, which was partially offset by increases at our Life Sciences and Spectrum segments. The decrease at our Infrastructure segment was primarily driven by the timing and size of projects, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business, at Banker Steel and DBMG's commercial structural steel fabrication and erection business, both of which had increased activity in the comparable period on certain large commercial construction projects that are now at or near completion in the current period. This was partially offset by an increase at the industrial maintenance and repair business as a result of an increase in project work. The increase at our Life Sciences segment was attributable to R2 Technologies, primarily driven by an increase in sales in North America and worldwide of all R2's products, including Glacial fx systems, consumables, Glacial Spa systems and Glacial Rx systems. The increase at our Spectrum segment was primarily driven by network launches and expanded coverage with existing customers.

*Income from operations*: Income from operations for the three months ended September 30, 2024, decreased $4.8 million to $5.9 million from $10.7 million for the three months ended September 30, 2023. The decrease was primarily due to a net decrease in gross profit of $10.5 million, which was partially offset by a decrease in selling, general and administrative ("SG&A") expenses of $6.4 million. The decrease in gross profit was primarily driven by our Infrastructure segment due to timing and size of projects that are now at or near completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business, partially offset by increases at our Spectrum segment driven by network launches and expanded coverage with existing customers and at our Life Sciences segment due to an increase in systems and consumables sales at R2 Technologies. The overall decrease in SG&A expenses was primarily driven by an unrepeated accounts receivable write-off of $2.2 million related to a customer bankruptcy in the comparable period and reductions in compensation-related expenses at our Infrastructure segment, unrepeated severance and reductions in compensation-related expenses at both our Non-Operating Corporate and our Spectrum segments. These decreases in SG&A expenses were partially offset by an increase in SG&A expenses at our Life Sciences segment, resulting from increases in selling fees paid by R2 Technologies, increased professional fees and higher sales commissions.

Income from operations for the nine months ended September 30, 2024, increased $25.0 million to $37.5 million from $12.5 million for the nine months ended September 30, 2023. The increase was due to a net increase in gross profit of $7.5 million, an increase in other operating income of $8.0 million, a decrease in SG&A expenses of $6.8 million and a decrease in depreciation and amortization of $2.7 million. The increase in gross profit was primarily driven by our Infrastructure segment, and, to a lesser extent, by our Spectrum and Life Sciences segments. The increase in gross profit at our Infrastructure segment was due to timing and size of projects that are now at or near completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business. The net increase in other operating income was driven by our Infrastructure segment primarily as a result of a gain on a lease modification and a gain on the sale of various properties in the current period, which was partially offset by a loss on disposal related to a plant closure in the first quarter of 2024. The overall decrease in SG&A was driven by unrepeated transaction expenses related to the sale of New Saxon's 19.0% investment in HMN in the comparable period, unrepeated severance and reductions in compensation-related expenses at both our Non-Operating Corporate and Spectrum segments, a decrease in consulting fees at our Non-Operating Corporate segment, a decrease in legal fees and facility-related expenses at our Infrastructure segment and decreases at our Life Sciences segment due to cost-reduction initiatives implemented in the second half of 2023 at R2 Technologies. The decreases in SG&A were partially offset by an increase in compensation-related expenses at our Infrastructure segment and, at our Life Sciences segment, increases in sales commissions and selling fees paid by R2 Technologies. The overall decrease in depreciation and amortization was primarily driven by our Infrastructure segment, as certain customer contract intangibles became fully amortized in the second quarter of 2023.

*Interest expense*: Interest expense for the three months ended September 30, 2024, increased $4.1 million to $21.2 million from $17.1 million for the three months ended September 30, 2023. The increase was primarily attributable to increases in exit fees and a higher outstanding principal balance at our Life Sciences segment as a result of new debt issued and capitalization of unpaid interest into principal balances subsequent to the comparable period, and, to a lesser extent, an increase at our Non-Operating Corporate segment, as well as an increase at our Spectrum segment due to additional exit fees incurred from a refinancing subsequent to the comparable period. This was partially offset by our Infrastructure segment due to a net decrease in outstanding principal balances.

Interest expense for the nine months ended September 30, 2024, increased $5.9 million to $54.9 million from $49.0 million for the nine months ended September 30, 2023. The increases were primarily attributable to increases in exit fees and a higher outstanding principal balance at our Life Sciences segment as a result of new debt issued and capitalization of unpaid interest into principal balances subsequent to the comparable period, an increase at our Non-Operating Corporate segment due to the issuance of the CGIC Unsecured Note in May 2023, which resulted in five months of interest in the comparable period compared to nine months of interest in the current period, and an increase in the Revolving Line of Credit balance subsequent to the comparable period, and, to a lesser extent, an increase in interest at our Spectrum segment due to additional exit fees incurred from a refinancing subsequent to the comparable period. This was partially offset by our Infrastructure segment due to a net decrease in outstanding principal balances.

*Loss from equity investees:* Loss from equity investees for the three months ended September 30, 2024, decreased $1.5 million to zero from a loss of $1.5 million for the three months ended September 30, 2023. The decrease in loss from equity investees was primarily due to a decrease in losses recognized from MediBeacon, as Pansend had no basis in MediBeacon against which to recognize any losses, and Pansend's carrying amount of its MediBeacon investment remained at zero. During the comparable period, Pansend made a $1.0 million convertible note investment in MediBeacon, allowing Pansend to recognize previously unrecognized unrealized equity method losses due to an increase in basis in the investment. Also contributing to the decrease in loss from equity investees was the partial sale of Triple Ring which was completed subsequent to the comparable period, and resulted in Pansend's investment in Triple Ring no longer being accounted for under the equity method of accounting. Thus, no equity method losses were recognized in the current period.

Loss from equity investees for the nine months ended September 30, 2024, decreased $3.5 million to $2.3 million from $5.8 million for the nine months ended September 30, 2023. The decrease in loss was due to a decrease in losses recognized from MediBeacon, Triple Ring and HMN. During the nine months ended September 30, 2024, as a result of additional convertible note investments in MediBeacon by Pansend, Pansend's basis in MediBeacon increased by $2.3 million and Pansend recognized $2.3 million of equity method losses that were previously unrecognized, whereas during the nine months ended September 30, 2023, as a result of an equity transaction with Huadong, Pansend's basis in MediBeacon had increased by $3.8 million and Pansend had recognized $3.8 million of equity method losses that were previously unrecognized, in addition to other equity method losses recognized for the period. As of both September 30, 2024 and 2023, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment. The partial sale of Triple Ring was completed subsequent to the comparable period and resulted in Pansend's investment in Triple Ring no longer being accounted for under the equity method of accounting. Our previous investment in HMN was sold on March 6, 2023 and had losses for the approximately two months of ownership in 2023. Thus, no equity method losses from Triple Ring or HMN were recognized in the current period. Refer to Note 6. Investments of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information on our equity investments.

*Other income, net:* Other income, net for the three months ended September 30, 2024, increased $1.8 million to $2.2 million from $0.4 million for the three months ended September 30, 2023. The increase was primarily driven by a $1.9 million gain on debt repurchase at our Non-Operating Corporate segment related to the partial repurchase of the 2026 Convertible Notes, an increase in interest income earned at our Life Sciences segment resulting from an increase in Pansend's convertible note receivable balance from MediBeacon subsequent to the comparable period, and our Non-Operating Corporate segment which earned additional interest income on its money market accounts due to an increase in outstanding deposited balances over the comparable period. This was partially offset by an increase in foreign currency translation losses from our Infrastructure segment.

Other income, net for the nine months ended September 30, 2024, decreased $16.0 million to $1.2 million from $17.2 million for the nine months ended September 30, 2023. The decrease was primarily driven by the unrepeated gain on the sale of the equity investment in HMN of $12.2 million in the comparable period, an unrepeated $3.8 million equity investment step-up gain from an increase in Pansend's basis as a result of MediBeacon issuing $7.5 million of its preferred stock to Huadong in the comparable period, a $2.2 million loss on debt extinguishment at R2 Technologies in the current period and an increase in foreign currency translation losses at our Infrastructure segment. The decrease was partially offset by a $1.9 million gain on debt repurchase at our Non-Operating Corporate segment related to the partial repurchase of the 2026 Convertible Note, an increase in interest income earned at our Life Sciences segment resulting from an increase in Pansend's convertible note receivable balance from MediBeacon subsequent to the comparable period, and our Non-Operating Corporate segment which earned additional interest income on its money market accounts due to an increase in outstanding deposited balances over the comparable period.

*Income tax expense*: Income tax expense for the three months ended September 30, 2024, increased $2.0 million to $3.1 million from $1.1 million for the three months ended September 30, 2023. Income tax expense for the nine months ended September 30, 2024, increased $0.7 million to $3.9 million from $3.2 million for the nine months ended September 30, 2023. The increases were primarily driven by the tax expense of INNOVATE's U.S. consolidated group utilizing its remaining unlimited NOLs in 2024 and due to the Tax Cut and Jobs Act's 80% limitation on net operating losses incurred after 2017, resulting in the annual effective tax rate for the current period being applied to the U.S. consolidated group's 2024 year-to-date income as calculated under ASC 740. The annual effective tax rate calculated for the comparable period interim tax provision included an unrepeated $1.1 million tax benefit, consisting of a current tax expense of $4.4 million related to a foreign tax payment and a deferred tax benefit of $5.5 million related to the reversal of the deferred tax liability associated with the $11.3 million put option, both of which were related to the sale of New Saxon's 19.0% investment in HMN on March 6, 2023.

The Organization for Economic Cooperation and Development ("OECD") has announced an Inclusive Framework on Base Erosion and Profit Shifting including a Pillar Two Model to provide for a 15% global minimum tax on the earnings of multinational corporations with consolidated revenue over €750 million. Many jurisdictions have enacted Pillar Two legislation that starts to become effective in 2024. The OECD, and its member countries, continue to release new guidance and legislation on Pillar Two. Based on current enacted laws, Pillar Two is not expected to materially impact our effective tax rate or cash flows in the next year. We will continue to evaluate the impact on our financial position as new legislation or guidance is introduced which could change our current assessment.

### Segment Results of Operations

In the Company's Condensed Consolidated Financial Statements, other operating (income) loss includes: (i) (gain) loss on sale or disposal of assets; (ii) lease termination costs and (gains) losses on lease modifications; (iii) asset impairment expense; (iv) accretion of asset retirement obligations; and (v) FCC reimbursements. Each table summarizes the results of operations of our operating segments (in millions).

### Infrastructure Segment

|  | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $232.8 | $369.3 | $(136.5) | $845.9 | $1,043.4 | $(197.5) |
| Cost of revenue | 189.1 | 313.1 | (124.0) | 695.7 | 896.8 | (201.1) |
| Selling, general and administrative | 28.3 | 32.9 | (4.6) | 93.0 | 93.3 | (0.3) |
| Depreciation and amortization | 3.0 | 2.6 | 0.4 | 8.9 | 11.6 | (2.7) |
| Other operating loss (income) | 0.1 | (0.2) | 0.3 | (8.8) | (0.2) | (8.6) |
| Income from operations | $12.3 | $20.9 | $(8.6) | $57.1 | $41.9 | $15.2 |

*Revenue:* Revenue for the three months ended September 30, 2024, decreased $136.5 million to $232.8 million from $369.3 million for the three months ended September 30, 2023. Revenue for the nine months ended September 30, 2024, decreased $197.5 million to $845.9 million from $1,043.4 million for the nine months ended September 30, 2023. The decreases were primarily driven by the timing and size of projects, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business, at Banker Steel and DBMG's commercial structural steel fabrication and erection business, both of which had increased activity in the comparable period on certain large commercial construction projects that are now at or near completion in the current period. This was partially offset by an increase at the industrial maintenance and repair business as a result of an increase in project work.

*Cost of revenue*: Cost of revenue for the three months ended September 30, 2024, decreased $124.0 million to $189.1 million from $313.1 million for the three months ended September 30, 2023. Cost of revenue for the nine months ended September 30, 2024, decreased $201.1 million to $695.7 million from $896.8 million for the nine months ended September 30, 2023. The decreases were primarily driven by the decrease in revenues at Banker Steel and DBMG's commercial structural steel fabrication and erection business from the timing of project activity on certain large commercial construction projects and decreases in costs as they wind down and near completion in the current period, which was partially offset by an increase in costs associated with the industrial maintenance and repair business as a result of an increase in project work.

*Selling, general and administrative*: Selling, general and administrative expense for the three months ended September 30, 2024, decreased $4.6 million to $28.3 million from $32.9 million for the three months ended September 30, 2023. The decrease was primarily driven by an unrepeated accounts receivable write-off of $2.2 million related to a customer bankruptcy in the comparable period, a decrease in expenses related to a foreign office closure in the comparable period, as well as a decrease due to timing of compensation-related expenses in the current period. This was partially offset by an increase in expenses related to a domestic plant closure incurred in the current period.

Selling, general and administrative expense for the nine months ended September 30, 2024, decreased $0.3 million to $93.0 million from $93.3 million for the nine months ended September 30, 2023. The decrease was primarily driven by an unrepeated accounts receivable write-off of $2.2 million related to a customer bankruptcy in the comparable period, a decrease in expenses related to a foreign office closure in the comparable period, a decrease in legal fees and facility-related expenses, which was mostly offset by an increase in compensation-related expenses and expenses related to a domestic plant closure and other restructuring costs incurred in the current period.

*Depreciation and amortization:* Depreciation and amortization for the three months ended September 30, 2024, increased $0.4 million to $3.0 million from $2.6 million for the three months ended September 30, 2023. Depreciation and amortization for the nine months ended September 30, 2024 decreased $2.7 million to $8.9 million from $11.6 million for the nine months ended September 30, 2023. The decrease for the nine months ended September 30, 2024 as compared to the comparable period was primarily driven by Banker Steel, as certain customer contract intangibles became fully amortized in the second quarter of 2023.

*Other operating loss (income)*: Other operating loss (income) was a loss of $0.1 million for the three months ended September 30, 2024, which decreased $0.3 million from income of $0.2 million for the three months ended September 30, 2023. Other operating (income) loss for the nine months ended September 30, 2024, increased $8.6 million to income of $8.8 million from $0.2 million for the nine months ended September 30, 2023. Other operating income for the nine months ended September 30, 2024, related to a gain on a lease modification and a gain on the sale of various properties in the current period, which was partially offset by a loss related to a plant closure in the first quarter of 2024.

### Life Sciences Segment

|  | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $3.0 | $0.6 | $2.4 | $5.7 | $1.8 | $3.9 |
| Cost of revenue | 2.0 | 0.5 | 1.5 | 3.7 | 1.4 | 2.3 |
| Selling, general and administrative | 4.2 | 3.3 | 0.9 | 12.2 | 11.7 | 0.5 |
| Depreciation and amortization | 0.1 | 0.1 | — | 0.3 | 0.3 | — |
| Loss from operations | $(3.3) | $(3.3) | $— | $(10.5) | $(11.6) | $1.1 |

*Revenue*: Revenue for the three months ended September 30, 2024 increased $2.4 million to $3.0 million from $0.6 million for the three months ended September 30, 2023. The increase in revenue was attributable to R2 Technologies, primarily due to an increase in Glacial fx system sales in North America, which launched during the comparable period, as well as from an increase in consumables sales both worldwide and in North America. In addition, the increase was partially driven by incremental Glacial Spa unit sales outside North America over the comparable period and from the launch of Glacial fx systems outside North America subsequent to the comparable period, as well as a slight increase in Glacial Rx systems sold in North America over the comparable period.

Revenue for the nine months ended September 30, 2024 increased $3.9 million to $5.7 million from $1.8 million for the nine months ended September 30, 2023. The increase in revenue was attributable to R2 Technologies, primarily due to incremental unit sales of the Glacial fx system in North America, which launched during the second half of 2023, as well as from an increase in consumable sales in both North America and worldwide. In addition, the increase was partially driven by an increase in Glacial Rx units sold in North America over the comparable period, as well as incremental sales from the launch of the Glacial fx systems outside North America subsequent to the comparable period and incremental Glacial Spa unit sales outside North America over the comparable period.

*Cost of revenue*: Cost of revenue for the three months ended September 30, 2024 increased $1.5 million to $2.0 million from $0.5 million for the three months ended September 30, 2023. Cost of revenue for the nine months ended September 30, 2024 increased $2.3 million to $3.7 million from $1.4 million for the nine months ended September 30, 2023. The increases in cost of revenue were attributable to R2 Technologies, primarily driven by the increases in revenue from the additional system sales noted above, changes in product mix sold as the Glacial fx and Glacial Spa systems have a lower production cost per system compared to the Glacial Rx, and, to a lesser extent, increases in royalty expenses, warranty expenses and freight costs driven by the additional systems sold.

*Selling, general and administrative*: Selling, general and administrative expense for the three months ended September 30, 2024 increased $0.9 million to $4.2 million from $3.3 million for the three months ended September 30, 2023. The increase was primarily driven by an increase in selling fees paid by R2 Technologies as well as slight increases in professional fees and sales commissions.

Selling, general and administrative expense for the nine months ended September 30, 2024 increased $0.5 million to $12.2 million from $11.7 million for the nine months ended September 30, 2023. The increase was primarily driven by increases in sales commissions at R2 Technologies due to an increase in system sales, an increase in selling fees paid by R2 Technologies, as well as an increase in professional fees, and an increase in research and development costs at Genovel. This was partially offset by other decreases in R2 Technologies general and administrative expenses including compensation-related expenses, travel and entertainment, and advertising and marketing expenses, as a result of continued cost reduction initiatives, which went into effect the second half of 2023.

### Spectrum Segment

|  | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $6.4 | $5.4 | $1.0 | $18.9 | $16.8 | $2.1 |
| Cost of revenue | 2.9 | 3.0 | (0.1) | 8.7 | 8.9 | (0.2) |
| Selling, general and administrative | 1.9 | 2.8 | (0.9) | 5.6 | 7.1 | (1.5) |
| Depreciation and amortization | 1.3 | 1.3 | — | 3.9 | 3.9 | — |
| Other operating loss | 0.4 | 0.4 | — | 0.5 | 0.1 | 0.4 |
| (Loss) income from operations | $(0.1) | $(2.1) | $2.0 | $0.2 | $(3.2) | $3.4 |

*Revenue:* Revenue for the three months ended September 30, 2024, increased $1.0 million to $6.4 million from $5.4 million for the three months ended September 30, 2023. Revenue for the nine months ended September 30, 2024, increased $2.1 million to $18.9 million from $16.8 million for the nine months ended September 30, 2023. The increases were primarily driven by network launches and expanded coverage with existing customers, which was partially offset by the termination of a number of smaller networks and individual markets during the comparable periods.

*Selling, general and administrative:* Selling, general and administrative expense for the three months ended September 30, 2024, decreased $0.9 million to $1.9 million from $2.8 million for the three months ended September 30, 2023. Selling, general and administrative expense for the nine months ended September 30, 2024, decreased $1.5 million to $5.6 million from $7.1 million for the nine months ended September 30, 2023. The decreases were primarily driven by unrepeated severance in the comparable period and a decrease in salaries and benefits expense as a result of a reduction in headcount.

*Other operating loss*: Other operating loss for the three months ended September 30, 2024, was $0.4 million driven by lease termination settlement costs incurred in the current period whereas the Other operating loss of $0.4 million for the three months ended September 30, 2023, was primarily driven by asset impairment charges related to certain redundant equipment and associated capitalized costs.

Other operating loss for the nine months ended September 30, 2024, increased $0.4 million to $0.5 million from $0.1 million for the nine months ended September 30, 2023. Other operating loss for the nine months ended September 30, 2024, was primarily comprised of lease termination settlement costs whereas the Other operating loss for the nine months ended September 30, 2023, was driven by asset impairment charges related to certain redundant equipment and associated capitalized costs which were partially offset by reimbursements received from the Federal Communications Commission (the "FCC") for certain station modification costs.

### Non-Operating Corporate

|  | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative | $3.0 | $4.8 | $(1.8) | $9.0 | $12.6 | $(3.6) |
| Depreciation and amortization | — | — | — | 0.1 | 0.1 | — |
| Other operating loss | — | — | — | 0.2 | — | 0.2 |
| Loss from operations | $(3.0) | $(4.8) | $1.8 | $(9.3) | $(12.7) | $3.4 |

*Selling, general and administrative*: Selling, general and administrative expenses for the three months ended September 30, 2024, decreased $1.8 million to $3.0 million from $4.8 million for the three months ended September 30, 2023, primarily driven by unrepeated severance expense related to the Company's former Chief Operating Officer in the comparable period and a decrease in stock-based compensation expense from the acceleration of awards related to our former CEO in the comparable period.

Selling, general and administrative expenses for the nine months ended September 30, 2024, decreased $3.6 million to $9.0 million from $12.6 million for the nine months ended September 30, 2023, primarily driven by unrepeated severance expense related to the Company's former Chief Operating Officer in the comparable period, a decrease in stock-based compensation expense from the acceleration of awards related to our former CEO in the comparable period, a decrease in salaries and benefits from a reduced headcount and a decrease in consulting fees.

*Other operating loss:* Other operating loss for the nine months ended September 30, 2024, increased to a loss of $0.2 million from zero for the nine months ended September 30, 2023, primarily driven by lease termination costs for two leases the Company exited in the current period.

### Loss from Equity Investees

|  | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Life Sciences | $— | $(1.5) | $1.5 | $(2.3) | $(5.5) | $3.2 |
| Other | — | — | — | — | (0.3) | 0.3 |
| Loss from equity investees | $— | $(1.5) | $1.5 | $(2.3) | $(5.8) | $3.5 |

*Life Sciences:* Loss from equity investees within our Life Sciences segment for the three months ended September 30, 2024, decreased $1.5 million to zero from a loss of $1.5 million for the three months ended September 30, 2023. The decrease in loss from equity investees was primarily due to a decrease in losses recognized from MediBeacon, as Pansend had no basis in MediBeacon against which to recognize any losses in the current period, and Pansend's carrying amount of its MediBeacon investment remained at zero. During the comparable period, Pansend made a $1.0 million convertible note investment in MediBeacon, allowing Pansend to recognize previously unrecognized equity method losses due to an increase in basis in the investment. Also contributing to the decrease in loss from equity investees was the partial sale of Triple Ring which was completed subsequent to the comparable period, and resulted in Pansend's investment in Triple Ring no longer being accounted for under the equity method of accounting. Thus, no equity method losses were recognized in the current period.

Loss from equity investees within our Life Sciences segment for the nine months ended September 30, 2024, decreased $3.5 million to $2.3 million from $5.8 million for the nine months ended September 30, 2023. The decrease in loss was primarily due to a decrease in losses recognized from MediBeacon and Triple Ring. During the nine months ended September 30, 2024, as a result of additional convertible note investments in MediBeacon by Pansend, Pansend's basis in MediBeacon increased by $2.3 million and Pansend recognized $2.3 million of equity method losses that were previously unrecognized, whereas during the nine months ended September 30, 2023, as a result of an equity transaction with Huadong, Pansend's basis in MediBeacon had increased by $3.8 million and Pansend had recognized $3.8 million of equity method losses that were previously unrecognized, in addition to other equity method losses recognized for the period. As of both September 30, 2024 and 2023, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment. The partial sale of Triple Ring was completed subsequent to the comparable period and resulted in Pansend's investment in Triple Ring no longer being accounted for under the equity method of accounting. Thus, no equity method losses were recognized from Triple Ring in the current period.

*Other:* Loss from equity investees within our Other segment for the nine months ended September 30, 2024, decreased $0.3 million to zero from a loss of $0.3 million for the nine months ended September 30, 2023. Loss from equity investees for the nine months ended September 30, 2023 was driven by our previous investment in HMN, which was sold on March 6, 2023, and had losses for the approximately two months of ownership in 2023.

Refer to Note 6. Investments of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, for additional information on our equity investments.

### Non-GAAP Financial Measures and Other Information

#### Adjusted EBITDA

Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, asset impairment expense and FCC reimbursements; interest expense; other (income) expense, net; income tax expense (benefit); non-controlling interest; share-based compensation expense; legacy accounts receivable write-offs; restructuring and exit costs; and acquisition and disposition costs.

Adjusted EBITDA by segment is summarized as follows:

| (in millions): | Three Months Ended September 30, 2024 | 2023 | Increase / (Decrease) | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Infrastructure | $20.9 | $30.8 | $(9.9) | $71.7 | $70.6 | $1.1 |
| Life Sciences | (3.0) | (4.3) | 1.3 | (12.0) | (16.0) | 4.0 |
| Spectrum | 1.7 | (0.3) | 2.0 | 4.8 | 0.9 | 3.9 |
| Non-Operating Corporate | (2.8) | (4.1) | 1.3 | (8.2) | (11.0) | 2.8 |
| Other and Eliminations | — | — | — | — | (1.0) | 1.0 |
| Adjusted EBITDA | $16.8 | $22.1 | $(5.3) | $56.3 | $43.5 | $12.8 |

48

The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp to Adjusted EBITDA for the three months ended September 30, 2024 and 2023:

*(in millions)*

|  | Three months ended September 30, 2024 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $6.2 | $(6.0) | $(5.6) | $(9.6) | $— | $(15.0) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 3.0 | 0.1 | 1.3 | — | — | 4.4 |
| Depreciation and amortization (included in cost of revenue) | 3.7 | — | — | — | — | 3.7 |
| Other operating loss | 0.1 | — | 0.4 | — | — | 0.5 |
| Interest expense | 3.0 | 4.5 | 3.8 | 9.9 | — | 21.2 |
| Other expense (income), net | 0.3 | (0.5) | 2.2 | (4.2) | — | (2.2) |
| Income tax expense | 2.3 | — | — | 0.8 | — | 3.1 |
| Non-controlling interest | 0.6 | (1.3) | (0.5) | — | — | (1.2) |
| Share-based compensation expense | — | 0.1 | — | 0.2 | — | 0.3 |
| Restructuring and exit costs | 1.4 | — | — | — | — | 1.4 |
| Acquisition and disposition costs | 0.3 | 0.1 | 0.1 | 0.1 | — | 0.6 |
| Adjusted EBITDA | $20.9 | $(3.0) | $1.7 | $(2.8) | $— | $16.8 |

*(in millions)*

|  | Three months ended September 30, 2023 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $10.8 | $(3.6) | $(6.5) | $(7.7) | $— | $(7.0) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 2.6 | 0.1 | 1.3 | — | — | 4.0 |
| Depreciation and amortization (included in cost of revenue) | 3.8 | — | — | — | — | 3.8 |
| Other operating (income) loss | (0.2) | — | 0.4 | — | — | 0.2 |
| Interest expense | 3.5 | 0.9 | 3.4 | 9.3 | — | 17.1 |
| Other (income) expense, net | (0.7) | (0.1) | 1.8 | (1.4) | — | (0.4) |
| Income tax expense (benefit) | 6.1 | — | — | (5.0) | — | 1.1 |
| Non-controlling interest | 1.0 | (1.8) | (0.8) | — | — | (1.6) |
| Share-based compensation expense | — | 0.2 | — | 0.6 | — | 0.8 |
| Legacy accounts receivable write-off | 2.2 | — | — | — | — | 2.2 |
| Restructuring and exit costs | 1.1 | — | 0.1 | — | — | 1.2 |
| Acquisition and disposition costs | 0.6 | — | — | 0.1 | — | 0.7 |
| Adjusted EBITDA | $30.8 | $(4.3) | $(0.3) | $(4.1) | $— | $22.1 |

*Infrastructure:* Net income from our Infrastructure segment for the three months ended September 30, 2024, decreased $4.6 million to $6.2 million from $10.8 million for the three months ended September 30, 2023. Adjusted EBITDA from our Infrastructure segment for the three months ended September 30, 2024, decreased $9.9 million to $20.9 million from $30.8 million for the three months ended September 30, 2023. The decrease in Adjusted EBITDA was primarily driven by lower revenue at both DBMG's commercial structural steel fabrication and erection business and Banker Steel, partially offset by higher margins, due to timing of completion of certain large commercial construction projects that are now at or near completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business, as well as lower margins at the construction modeling and detailing business. This was partially offset by an increase in revenue and margins at the industrial maintenance and repair business and a decrease in recurring SG&A expenses primarily as a result of a decrease due to timing of compensation-related expenses in the current period.

*Life Sciences:* Net loss from our Life Sciences segment for the three months ended September 30, 2024, increased $2.4 million to $6.0 million from $3.6 million for the three months ended September 30, 2023. Adjusted EBITDA loss from our Life Sciences segment for the three months ended September 30, 2024, decreased $1.3 million to $3.0 million from $4.3 million for the three months ended September 30, 2023. The decrease in Adjusted EBITDA loss was primarily due to a decrease in equity method losses recognized from MediBeacon and Triple Ring, as discussed in *Loss from Equity Investees* above. Additionally contributing to the decrease in Adjusted EBITDA loss was an increase in gross profit at R2 Technologies, driven by an increase in sales in North America and worldwide of all R2's products, including Glacial fx systems, consumables, Glacial Spa systems and Glacial Rx systems. The decrease in Adjusted EBITDA loss was partially offset by an increase in SG&A expenses at R2 Technologies, primarily as a result of an increase in selling fees.

*Spectrum:* Net loss from our Spectrum segment for the three months ended September 30, 2024, decreased $0.9 million to $5.6 million from $6.5 million for the three months ended September 30, 2023. Adjusted EBITDA from our Spectrum segment for the three months ended September 30, 2024, increased $2.0 million to $1.7 million from an Adjusted EBITDA loss of $0.3 million for the three months ended September 30, 2023. The increase in Adjusted EBITDA was primarily due to an increase in revenue driven by network launches and expanded coverage with existing customers and unrepeated severance in the comparable period, which was partially offset by the termination of a number of smaller networks and individual markets in the comparable period.

*Non-Operating Corporate:* Net loss from our Non-Operating Corporate segment for the three months ended September 30, 2024, increased $1.9 million to $9.6 million from $7.7 million for the three months ended September 30, 2023. Adjusted EBITDA loss from our Non-Operating Corporate segment for the three months ended September 30, 2024, decreased $1.3 million to $2.8 million from $4.1 million for the three months ended September 30, 2023. The decrease in Adjusted EBITDA loss was primarily driven by unrepeated severance expense related to the Company's former Chief Operating Officer in the comparable period.

The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp to Adjusted EBITDA for the nine months ended September 30, 2024 and 2023:

*(in millions)*

|  | Nine months ended September 30, 2024 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $31.6 | $(14.3) | $(15.4) | $(20.0) | $0.1 | $(18.0) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 8.9 | 0.3 | 3.9 | 0.1 | — | 13.2 |
| Depreciation and amortization (included in cost of revenue) | 11.5 | 0.1 | — | — | — | 11.6 |
| Other operating (income) loss | (8.8) | — | 0.5 | 0.2 | — | (8.1) |
| Interest expense | 7.7 | 6.4 | 10.6 | 30.2 | — | 54.9 |
| Other (income) expense, net | (0.8) | 1.2 | 6.3 | (7.8) | (0.1) | (1.2) |
| Income tax expense (benefit) | 15.7 | — | — | (11.8) | — | 3.9 |
| Non-controlling interest | 3.0 | (6.1) | (1.3) | — | — | (4.4) |
| Share-based compensation expense | — | 0.3 | — | 0.8 | — | 1.1 |
| Restructuring and exit costs | 2.6 | — | — | — | — | 2.6 |
| Acquisition and disposition costs | 0.3 | 0.1 | 0.2 | 0.1 | — | 0.7 |
| Adjusted EBITDA | $71.7 | $(12.0) | $4.8 | $(8.2) | $— | $56.3 |

50

*(in millions)*

|  | Nine Months Ended September 30, 2023 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $19.8 | $(9.3) | $(16.8) | $(27.8) | $8.2 | $(25.9) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 11.6 | 0.3 | 3.9 | 0.1 | — | 15.9 |
| Depreciation and amortization (included in cost of revenue) | 11.7 | 0.1 | — | — | — | 11.8 |
| Other operating (income) loss | (0.2) | — | 0.1 | — | — | (0.1) |
| Interest expense | 10.3 | 2.1 | 10.0 | 26.6 | — | 49.0 |
| Other (income) expense, net | (1.2) | (4.1) | 5.5 | (4.9) | (12.5) | (17.2) |
| Income tax expense (benefit) | 11.0 | — | — | (6.6) | (1.2) | 3.2 |
| Non-controlling interest | 1.9 | (5.6) | (2.0) | — | 3.3 | (2.4) |
| Share-based compensation expense | — | 0.5 | — | 1.5 | — | 2.0 |
| Legacy accounts receivable write-off | 2.2 | — | — | — | — | 2.2 |
| Restructuring and exit costs | 2.1 | — | 0.1 | — | — | 2.2 |
| Acquisition and disposition costs | 1.4 | — | 0.1 | 0.1 | 1.2 | 2.8 |
| Adjusted EBITDA | $70.6 | $(16.0) | $0.9 | $(11.0) | $(1.0) | $43.5 |

*Infrastructure:* Net income from our Infrastructure segment for the nine months ended September 30, 2024, increased $11.8 million to $31.6 million from $19.8 million for the nine months ended September 30, 2023. Adjusted EBITDA from our Infrastructure segment for the nine months ended September 30, 2024, increased $1.1 million to $71.7 million from $70.6 million for the nine months ended September 30, 2023. The increase in Adjusted EBITDA was primarily driven by higher margins on certain large commercial construction projects that are now at or near completion in the current period at DBMG's commercial structural steel fabrication and erection, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business, despite the decrease in revenue, and increases in revenue and margins at the industrial maintenance and repair businesses, which was partially offset by a decrease in revenue at Banker Steel, despite an increase in margins, due to timing of completion of certain large commercial construction projects, an increase in recurring SG&A, primarily as a result of compensation-related expenses, and decreased margins at the construction modeling and detailing business.

*Life Sciences:* Net loss from our Life Sciences segment for the nine months ended September 30, 2024, increased $5.0 million to $14.3 million from $9.3 million for the nine months ended September 30, 2023. Adjusted EBITDA loss from our Life Sciences segment for the nine months ended September 30, 2024, decreased $4.0 million to $12.0 million from $16.0 million for the nine months ended September 30, 2023. The decrease in Adjusted EBITDA loss was primarily due to a decrease in equity method losses recognized from MediBeacon and Triple Ring, as discussed in *Loss from Equity Investees* above. Additionally contributing to the decrease in Adjusted EBITDA loss was an increase in gross profit at R2 Technologies, driven by an increase in sales in North America and worldwide of all R2's products, including Glacial fx systems, consumables, Glacial Spa systems and Glacial Rx systems. In addition, certain SG&A expenses at R2 Technologies decreased due to cost reduction initiatives which went into effect in the second half of 2023, which were offset by increases in sales commissions due to an increase in system sales, an increase in selling fees, an increase in professional fees and an increase research and development costs at Genovel.

*Spectrum:* Net loss from our Spectrum segment for the nine months ended September 30, 2024, decreased $1.4 million to $15.4 million from $16.8 million for the nine months ended September 30, 2023. Adjusted EBITDA from our Spectrum segment for the nine months ended September 30, 2024, increased $3.9 million to $4.8 million from $0.9 million for the nine months ended September 30, 2023. The increase in Adjusted EBITDA was primarily due to an increase in revenue primarily driven by network launches and expanded coverage with existing customers, unrepeated severance in the comparable period, as well as a decrease in salaries and benefits expense. This was partially offset by the termination of a number of smaller networks and individual markets in the comparable period.

*Non-Operating Corporate:* Net loss from our Non-Operating Corporate segment for the nine months ended September 30, 2024, decreased $7.8 million to $20.0 million from $27.8 million for the nine months ended September 30, 2023. Adjusted EBITDA loss from our Non-Operating Corporate segment for the nine months ended September 30, 2024 decreased $2.8 million to $8.2 million from $11.0 million for the nine months ended September 30, 2023. The decrease in Adjusted EBITDA loss was primarily driven by an unrepeated severance expense related to the Company's former Chief Operating Officer in the comparable period, a decrease in salaries and benefits from a reduced headcount, and a decrease in consulting fees.

*Other and Eliminations:* Net income from our Other segment and Eliminations for the nine months ended September 30, 2024, decreased $8.1 million to $0.1 million from $8.2 million for the nine months ended September 30, 2023. Adjusted EBITDA losses from our Other segment for the nine months ended September 30, 2024, decreased $1.0 million to zero from an Adjusted EBITDA loss of $1.0 million for the nine months ended September 30, 2023. The decrease in Adjusted EBITDA loss was driven primarily by unrepeated severance related expenses at TIC Holdco, Inc. in the comparable period and our previous investment in HMN, which was sold on March 6, 2023, and had equity method losses for the approximately two months of ownership in 2023.

### Backlog

Projects in backlog consist of awarded contracts, letters of intent, notices to proceed, change orders, and purchase orders obtained. Backlog increases as contract commitments are obtained, decreases as revenues are recognized and increases or decreases to reflect modifications in the work to be performed under the contracts. Backlog is converted to sales in future periods as work is performed or projects are completed. Backlog can be significantly affected by the receipt or loss of individual contracts.

#### Infrastructure Segment

As of September 30, 2024, DBMG's backlog was $916.1 million, consisting of $823.7 million under contracts or purchase orders and $92.4 million under letters of intent or notices to proceed. Approximately $418.0 million, representing 45.6% of DBMG’s backlog as of September 30, 2024, was attributable to five contracts, letters of intent, notices to proceed or purchase orders. If one or more of these projects terminate or reduce their scope, DBMG’s backlog could decrease substantially. DBMG includes an additional $12.1 million in its backlog that is not included in the remaining unsatisfied performance obligations disclosed in Note 3. Revenue and Contracts in Process. This additional backlog includes commitments under master service agreements that are estimated amounts of work to be performed based on customer communications, historic performance and knowledge of our customers' intentions.

### Liquidity and Capital Resources

### Short- and Long-Term Liquidity Considerations and Risks

Our Non-Operating Corporate segment consists of holding companies, and its liquidity needs are primarily for interest payments on its 2026 Senior Secured Notes, 2026 Convertible Notes, Revolving Line of Credit, CGIC Unsecured Note, and dividend payments on its Series A-3 and Series A-4 Preferred Stock and recurring operational expenses.

On a consolidated basis, as of September 30, 2024, we had $51.0 million of cash and cash equivalents, excluding restricted cash, compared to $80.8 million as of December 31, 2023. On a stand-alone basis, as of September 30, 2024, our Non-Operating Corporate segment had cash and cash equivalents, excluding restricted cash, of $20.2 million compared to $2.5 million as of December 31, 2023.

Our subsidiaries' principal liquidity requirements arise from cash used in operating activities, debt service, and capital expenditures, including purchases of steel construction equipment, OTA broadcast station equipment, development of back-office systems, operating costs and expenses, and income taxes.

As of September 30, 2024, we had $699.2 million of principal indebtedness on a consolidated basis compared to $722.8 million as of December 31, 2023, a net decrease of $23.6 million, which was primarily due to a $22.0 million net decrease in debt at our Infrastructure segment and a $7.0 million decrease in debt at our Non-Operating Corporate segment, partially offset by the capitalization of unpaid accrued interest at R2 Technologies into the principal amount of $5.4 million.

On a stand-alone basis, our Non-Operating Corporate segment indebtedness was $429.9 million and $436.9 million as of September 30, 2024 and December 31, 2023, respectively, a decrease of $7.0 million driven by a partial redemption payment of $4.1 million of the CGIC Unsecured Note on April 26, 2024 and the repurchase of $2.9 million principal amount of 2026 Convertible Notes during the nine months ended September 30, 2024. The September 30, 2024 indebtedness balance consists of the $330.0 million aggregate principal amount of 2026 Senior Secured Notes, $48.9 million aggregate principal amount of 2026 Convertible Notes, $31.0 million remaining principal amount of the CGIC Unsecured Note and $20.0 million aggregate principal amount drawn on our Revolving Line of Credit. Our Non-Operating Corporate segment is required to make semi-annual interest payments on the 2026 Senior Secured Notes and 2026 Convertible Notes on February 1st and August 1st of each year, quarterly interest payments on the Revolving Line of Credit, and monthly interest payments on the CGIC Unsecured Note. As described below, the interest rate on the CGIC Unsecured Note increased from 9.0% per annum to 16.0% per annum on May 9, 2024, and will increase from 16.0% per annum to 32.0% per annum on May 9, 2025.

We are required to make dividend payments on our outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock on January 15th, April 15th, July 15th, and October 15th of each year.

Our Non-Operating Corporate segment received $1.4 million and $8.0 million in net tax sharing payments from our Infrastructure segment for the three and nine months ended September 30, 2024, respectively. In addition, DBMG redeemed the intercompany $41.8 million DBMG Series A Preferred Stock from DBMGi on June 28, 2024, for $41.8 million in cash, which was remitted to INNOVATE. DBM Global Intermediate Holdco Inc. ("DBMGi") is a 100% owned subsidiary of INNOVATE and all intercompany transactions are eliminated on consolidation.

We have financed our growth and operations to date, and expect to finance our future growth and operations, through public offerings and private placements of debt and equity securities, credit facilities, vendor financing, finance lease financing and other financing arrangements, as well as cash generated from the operations of our subsidiaries. In the future, we may also choose to sell assets or certain investments to generate cash.

### Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a $19.0 million rights offering ("Rights Offering") for its common stock. Pursuant to the Rights Offering, the Company distributed to each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), transferable subscription rights to purchase 0.2858 shares of the Company’s common stock at a price of $0.70 per whole share (on a pre Reverse Stock Split basis).

Per the concurrent investment agreement entered into with Lancer Capital (the "Investment Agreement"), the Rights Offering was backstopped by Lancer Capital, an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. Due to limitations on the common stock that can be issued to Lancer Capital under the rules of the New York Stock Exchange ("NYSE"), in lieu of exercising its subscription rights, pursuant to the Investment Agreement, Lancer Capital would purchase up to $19.0 million of the Company’s newly issued Series C Non-Voting Participating Convertible Preferred Stock (the “Series C Preferred Stock”), for an issue price of $1,000 per share. In connection with the backstop commitment, and as a result of limitations in the amount common equity that can be raised under the Company’s effective shelf registration statement on Form S-3, Lancer Capital also agreed to purchase an additional $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement") which was to close concurrently with the settlement of the Rights Offering. Lancer Capital did not receive any compensation or other consideration for entering into or consummating the Investment Agreement.

As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock (5,306,105 shares of common stock on a pre Reverse Stock Split basis) for $3.7 million. Based on the number of shares of common stock actually sold upon exercise of the rights to third party investors, there were no excess shares of Series C Preferred Stock purchased by Lancer Capital under the equity advance that the Company was required to redeem, and Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the backstop commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which have been capitalized into Additional paid in capital ("APIC"). INNOVATE has been utilizing and expects to continue to use the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and working capital. In addition, as a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Unsecured Note, and consequently, on April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note.

Under the rules of the NYSE, because the shares purchased by Lancer Capital were greater than 20% of the Company's common stock outstanding before the issuance of the Series C Preferred Stock, those shares of Series C Preferred Stock were not allowed to be converted until stockholder approval of such issuance was obtained. On June 18, 2024, the Company held its annual shareholder meeting where Company's shareholder's approved the conversion of the Series C Preferred Stock into common stock. As a result, approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock (44,693,895 shares of common stock on a pre Reverse Stock Split basis).

The Company waived its Tax Benefits Preservation Plan to permit persons exercising rights to acquire 4.9% or more of the outstanding common stock upon the exercise thereof without becoming an Acquiring Person (as defined in the Tax Benefits Preservation Plan).

INNOVATE has used and expects to continue to use the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and for working capital. As a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Unsecured Note, in the amount of the greater of $3.0 million or 12.5% of the net proceeds. On April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note. See Note 15. Equity and Temporary Equity for additional information.

### Going Concern

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities of current debt at certain of the Company's subsidiaries as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next 12 months.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The inability to refinance or extend the maturity of the current debt at the Company's subsidiaries, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

The Company plans to alleviate these conditions through various initiatives it is currently exploring, including refinancing the debt at Broadcasting and DBMG, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

The unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

### Capital Expenditures

Capital expenditures are set forth in the table below (in millions):

|  | Three Months Ended September 30, 2024 | 2023 | Nine Months Ended September 30, 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| Infrastructure | $2.8 | $5.5 | $10.7 | $12.5 |
| Life Sciences | — | — | 0.1 | 0.3 |
| Spectrum | 0.3 | 0.2 | 1.0 | 0.8 |
| Non-Operating Corporate | — | — | — | 0.3 |
| Total | $3.1 | $5.7 | $11.8 | $13.9 |

### Indebtedness

### Non-Operating Corporate

#### 2026 Senior Secured Notes

On February 1, 2021, our Non-Operating Corporate segment repaid the senior secured notes that were due in 2021 and issued $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "2026 Senior Secured Notes"). The 2026 Senior Secured Notes mature on February 1, 2026, and accrue interest at a rate of 8.50% per year, which interest is paid semi-annually on February 1st and August 1st of each year. If the Company sells certain assets and the net cash proceeds from all applicable asset sales exceed $50.0 million since the issue date of the 2026 Senior Secured Notes, the Company may be required in certain circumstances to make an offer to purchase the notes with the net cash proceeds from such an asset sale in excess of such $50.0 million threshold at a price in cash equal to 101% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase. For additional information on the terms and conditions of the 2026 Senior Secured Notes, including guarantees, ranking and collateral, refer to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2023 Annual Report on Form 10-K, which was filed with the SEC on March 6, 2024.

#### 2026 Convertible Notes

The original $51.8 million aggregate principal amount of 7.50% convertible notes (the "2026 Convertible Notes") were issued under a separate indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee (the "Convertible Indenture"). In July 2024, we repurchased $2.9 million principal amount of our 2026 Convertible Notes at a market discount for $1.1 million, which is inclusive of accrued interest of $0.1 million. As of September 30, 2024, we had $48.9 million principal amount of 2026 Convertible Notes outstanding. The 2026 Convertible Notes mature on August 1, 2026 unless earlier converted, redeemed or purchased. The 2026 Convertible Notes accrue interest at a rate of 7.5% per year, which interest is paid semi-annually on February 1st and August 1st of each year.

For additional information on the terms and conditions of the 2026 Convertible Notes, including optional redemption, conversion rights guarantees, ranking and collateral, refer to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2023 Annual Report on Form 10-K, which was filed with the SEC on March 6, 2024.

Our debt contains customary events of default which could, subject to certain conditions, cause the 2026 Senior Secured Notes and the 2026 Convertible Notes to become immediately due and payable.

#### Revolving Line of Credit

We have a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD") which has a maximum commitment of $20.0 million ("Revolving Line of Credit"), of which $20.0 million had been drawn as of September 30, 2024. Interest on loans under the Revolving Line of Credit accrues at SOFR plus 5.75% and is payable quarterly. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based off the actual daily amount of unused availability under the Revolving Line of Credit with MSD. The maturity date of the Revolving Line of Credit, as amended on May 6, 2024, is May 16, 2025. The amount outstanding under the Revolving Line of Credit is subject to mandatory prepayment from the net cash proceeds from certain asset sales in excess of $10.0 million.

For additional information on the terms and conditions of the Revolving Line of Credit, including guarantees and ranking and collateral, refer to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2023 Annual Report on Form 10-K, which was filed with the SEC on March 6, 2024.

#### CGIC Unsecured Note

On May 9, 2023, in connection with the redemption of the DBMGi Series A Preferred Stock, the Company issued a subordinated unsecured promissory note to CGIC in the principal amount of $35.1 million (the "CGIC Unsecured Note"). The CGIC Unsecured Note is due February 28, 2026, and bore interest at 9.0% per annum through May 8, 2024, bears interest at 16.0% per annum from May 9, 2024 to May 8, 2025, and 32.0% per annum thereafter. The CGIC Unsecured Note also requires a mandatory prepayment from the proceeds from certain asset sales and the greater of $3.0 million or 12.5% of the net proceeds from certain equity sales. Other covenants in the CGIC Unsecured Note are generally consistent with the Company's Indenture governing the 8.50% Senior Secured Notes due 2026, dated as of February 1, 2021, by and among the Company, the guarantors party thereto and U.S. Bank National Association. As a result of the closing of the Rights Offering on April 24, 2024, INNOVATE redeemed $4.1 million of the CGIC Unsecured Note on April 26, 2024. Refer to Note 15. Temporary Equity and Equity and to Note 11. Debt Obligations included in the Consolidated Financial Statements included in our 2023 Annual Report on Form 10-K, which was filed with the SEC on March 6, 2024, for additional information, as well as Note 15. Equity and Temporary Equity included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional details regarding the $4.1 million partial redemption.

### Infrastructure

As of September 30, 2024, our Infrastructure segment has aggregate principal outstanding debt, including obligations under finance leases, of $176.8 million.

DBMG has a $135.0 million Revolving Line with UMB that bears interest at a prime rate minus a spread with an interest rate floor of 4.25%. As of September 30, 2024 the outstanding balance was $75.0 million. The effective interest rate on the Revolving Line with UMB was 7.52% and 8.33% as of September 30, 2024 and December 31, 2023, respectively. The Revolving Line with UMB matures on August 15, 2025, and interest is paid monthly. The Revolving Line with UMB also includes a commitment fee equal to 0.25% per annum times the average daily unused availability under the line. DBMG also has a $76.3 million term loan due 2026 (the "3.25% UMB Term Loan"), which expires May 31, 2026, and bears interest at an annual rate of 3.25% with an effective interest rate of 3.3%. Interest is paid monthly.

On June 28, 2024, DBM and UMB entered into the Third Amendment to the UMB Credit Agreement. The amendment adds an incremental separate term loan of $25.0 million to the existing credit facility, with the same interest rate as the Revolving Line with UMB and the same maturity date as the initial $76.3 million 3.25% UMB Term Loan. Principal payments and interest are paid monthly.

During the nine months ended September 30, 2024, DBMG made $5.0 million in scheduled payments on the 4.0% note that was payable to Banker Steel's former owner. The 4.0% note matured on March 31, 2024 and was fully redeemed on April 2, 2024.

Refer to Note 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q which is incorporated herein by reference, for additional details regarding the indebtedness of our Infrastructure segment.

### Life Sciences

As of September 30, 2024, our Life Sciences segment has aggregate principal outstanding debt of $22.8 million.

R2 Technologies had various short-term notes with Lancer Capital, which expired on January 31, 2024, and, effective January 31, 2024, a new 20% note with an aggregate original principal amount of $20.0 million was issued, which was comprised of all prior outstanding principal amounts and unpaid accrued interest of $2.6 million which was capitalized into the new principal balance. Interest on the note accrues at 20% per annum and is payable monthly in arrears, in cash or, if not paid in cash, accrued and unpaid interest is capitalized monthly into the principal balance. The 20% $20.0 million note also includes an exit fee of 10.5% of the principal amount being repaid if repaid anytime from April 1, 2024 through April 30, 2024. The original maturity date of the 20% $20.0 million note was April 30, 2024, or within five business days of the date on which R2 Technologies receives an aggregate $20.0 million from the consummation of a debt or equity financing or has a change in control, as defined in the agreement, with an optional prepayment of the entire then-outstanding and unpaid principal and accrued interest upon five-days written notice to Lancer Capital. Effective May 17, 2024, the maturity date of the note was extended to December 31, 2024, and the exit fees were amended.

The initial exit fee, as amended, as of September 30, 2024 was equal to 11.39% of the principal amount being repaid and continues to increase by 0.17% each month thereafter until maturity. Effective July 31, 2024, an additional exit fee of $1.0 million was incurred under the amendment, which increases by $1.0 million each month until the end of November 2024. If unpaid prior to maturity, the total exit fees payable will be $7.9 million. The exit fees are being amortized over the term of the note using the effective interest rate method and are included in interest expense. The exit fees are payable on the earliest of the maturity date, the date of the acceleration of the principal amount of the note for any reason or, if any portion of the note is prepaid at any time, the date of such prepayment of the note. As of September 30, 2024, total accrued exit fees were $5.6 million and were included within Accrued liabilities on the Condensed Consolidated Balance Sheet. Refer to Note 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Spectrum

As of September 30, 2024, our Spectrum segment has aggregate principal outstanding debt of $69.7 million, consisting of 8.50% and 11.45% Notes. Interest is capitalized and payable upon maturity of the notes. The maturity date of Spectrum's 8.50% and 11.45% Notes, is August 15, 2025, as amended.

The exit fees associated with the notes, which are payable on the earlier of maturity or repayment of the principal, were recorded as original issue discount and are being amortized over the remaining life of the notes, which is assumed to be the maturity date. A corresponding liability of $15.9 million is reflected within Other Current Liabilities in the Condensed Consolidated Balance Sheet as of September 30, 2024, and a corresponding liability of $15.9 million was reflected within Other Liabilities (non-current) in the Consolidated Balance Sheet as of December 31, 2023. As of September 30, 2024, the effective interest rates on the notes, as amended, ranged from 20.6% to 24.0% per annum.

During November 2023, concurrently with Broadcasting's execution of the Ninth Amendment to Secured Notes, which among other things extended the maturity of the notes, INNOVATE entered into a related side letter with the lenders, whereby INNOVATE agreed to utilize proceeds from the sale of certain of its existing operations, as allowable under the Company's current agreements and indentures and after all other required payments have been made, for repayment of a portion of our Spectrum segment's Senior Secured Notes. Assuming there are sufficient proceeds remaining after such repayment, an additional $1.0 million fee is payable if repayment occurs by November 9, 2024, or $2.0 million if repayment occurs after that date. In exchange for the additional fee, the institutional investors will return their equity interests in HC2 Broadcasting Holdings, Inc. and their equity interests in DTV America.

Refer to Note 11. Debt Obligations of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Restrictive Covenants

The indenture governing the 2026 Senior Secured Notes dated February 1, 2021, by and among INNOVATE, the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee (the "Secured Indenture"), contains certain affirmative and negative covenants limiting, among other things, the ability of the Company, and, in certain cases, the Company’s subsidiaries, to incur additional indebtedness; create liens; engage in sale-leaseback transactions; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. These covenants are subject to a number of important exceptions and qualifications.

The Company is also required to comply with certain financial maintenance covenants, which are similarly subject to a number of important exceptions and qualifications. These covenants include maintenance of (1) liquidity and (2) collateral coverage.

The maintenance of liquidity covenant provides that the Company will not permit the aggregate amount of (i) all unrestricted cash and Cash Equivalents of the Company and the Subsidiary Guarantors, (ii) amounts available for drawing under revolving credit facilities and undrawn letters of credit of the Company and the Subsidiary Guarantors and (iii) dividends, distributions or payments that are immediately available to be paid to the Company by any of its Restricted Subsidiaries to be less than the Company’s obligation to pay interest for the next six months on the 2026 Senior Secured Notes and all other Debt, including Convertible Series A-3 and Series A-4 Preferred Stock mandatory cash dividends or any other mandatory cash pay Series A-3 and Series A-4 Preferred Stock but excluding any obligation to pay interest on Series A-3 and Series A-4 Preferred Stock or any other mandatory cash payments on Series A-3 and Series A-4 Preferred Stock which, in each case, may be paid by accretion or in-kind in accordance with its terms of the Company and its Subsidiary Guarantors. As of September 30, 2024, the Company was in compliance with this covenant.

The maintenance of collateral coverage provides that the certain subsidiaries' Collateral Coverage Ratio (as defined in the Secured Indenture as the ratio of (i) the Loan Collateral to (ii) Consolidated Secured Debt (each as defined therein)) calculated on a pro forma basis as of the last day of each fiscal quarter may not be less than 1.50 to 1.00. As of September 30, 2024, the Company was in compliance with this covenant.

The instruments governing the Company’s Series A-3 Preferred Stock and Series A-4 Preferred Stock also limit the Company’s and its subsidiaries ability to take certain actions, including, among other things, to incur additional indebtedness; issue additional Series A-3 Preferred Stock and Series A-4 Preferred Stock; engage in transactions with affiliates; and make certain restricted payments. These limitations are subject to a number of important exceptions and qualifications.

The Company has conducted its operations in a manner that has resulted in compliance with the Secured Indenture; however, compliance with certain financial covenants for future periods may depend on the Company or one or more of the Company’s subsidiaries undertaking one or more non-operational transactions, such as the management of operating cash outflows, a monetization of assets, a debt incurrence or refinancing, the raising of equity capital, or similar transactions. If the Company is unable to remain in compliance and does not make alternate arrangements, an event of default would occur under the Company’s Secured Indenture which, among other remedies, could result in the outstanding obligations under the indenture becoming immediately due and payable and permitting the exercise of remedies with respect to the collateral. There is no assurance the Company will be able to complete any non-operational transaction it may undertake to maintain compliance with covenants under the Secured Indenture or, even if the Company completes any such transaction, that it will be able to maintain compliance for any subsequent period.

The UMB term loans and Revolving Line with UMB associated with our Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, as defined in the agreement.

As of September 30, 2024, we were in compliance with the covenants of our debt agreements.

### Summary of Consolidated Cash Flows

The below table summarizes the cash provided by or used in our activities (in millions):

|  | Nine Months Ended September 30, 2024 | 2023 | Increase / (Decrease) |
| --- | ---: | ---: | ---: |
| Cash used in operating activities | $(32.3) | $(34.7) | $2.4 |
| Cash (used in) provided by investing activities | (4.0) | 41.2 | (45.2) |
| Cash provided by (used in) financing activities | 6.4 | (30.6) | 37.0 |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | 0.1 | (1.0) | 1.1 |
| Net decrease in cash and cash equivalents, including restricted cash | $(29.8) | $(25.1) | $(4.7) |

#### Operating Activities

Cash used in operating activities was $32.3 million for the nine months ended September 30, 2024, as compared to $34.7 million for the nine months ended September 30, 2023, an improvement of $2.4 million. Cash flows from operations are primarily influenced by changes in the timing of demand for services and by operating margins, but can also be affected by working capital needs associated with our operations. For the nine months ended September 30, 2024, the improvement in operating cash flows was primarily driven by our Non-Operating Corporate segment, which had reductions in SG&A expenses related to unrepeated severance payments in the prior period and reductions in salaries and benefits in the current period due to headcount decreases, and our Other segment, which had an unrepeated $4.4 million foreign tax payment in the prior period related to the sale of New Saxon's 19% investment in in HMN on March 6, 2023. This was partially offset by a net decrease in working capital cash flows at our Infrastructure segment, primarily driven by normal business fluctuations in accounts receivable, contract-related assets and liabilities, other accrued liabilities and other current liabilities.

#### Investing Activities

Cash used in investing activities was $4.0 million for the nine months ended September 30, 2024, as compared to cash provided by investing activities of $41.2 million for the nine months ended September 30, 2023, a decrease of $45.2 million. The decrease was primarily driven by the $54.2 million of gross cash proceeds received in the prior period from the sale of New Saxon's 19.0% investment in HMN on March 6, 2023. Partially offsetting this decrease, was an increase in proceeds from the disposal of PP&E, which totaled $9.9 million for the nine months ended September 30, 2024 and primarily related to the sale of various PP&E at our Infrastructure segment, as compared to $1.5 million in proceeds for the nine months ended September 30, 2023. Capital expenditures for the nine months ended September 30, 2024 were $11.8 million, as compared to $13.9 million for the nine months ended September 30, 2023, a decrease in cash used of $2.1 million. Loans made by our Life Sciences segment to MediBeacon totaled $2.3 million for the nine months ended September 30, 2024, as compared to $1.0 million for the nine months ended September 30, 2023, a decrease of $1.3 million.

#### Financing Activities

Cash provided by financing activities was $6.4 million for the nine months ended September 30, 2024, as compared to cash used in financing activities of $30.6 million for the nine months ended September 30, 2023, an improvement in financing cash flows of $37.0 million. The improvement was primarily driven by our Non-Operating Corporate segment, which received $33.2 million in net proceeds in the current period from the Rights Offering and Concurrent Private Placement. In addition, during the nine months ended September 30, 2023, we made $15.9 million in distributions to non-controlling interests and redeemable non-controlling interests related to the sale of New Saxon's 19.0% investment in HMN on March 6, 2023. Our Corporate Segment also made a $7.0 million payment in the prior period connection with the repurchase of the DBMGi Series A Preferred Stock on May 9, 2023 from CGIC, and dividend payments decreased by $0.9 million for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023, due to the repurchase of the DBMGi Series A Preferred Stock. These improvements in financing cash flows were partially offset by a $35.0 million increase in net outflows from revolving credit line activity for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023, which includes a net $25.0 million payment in the current period and included net proceeds of $10.0 million in the prior period related to our Infrastructure segment's Revolving Line with UMB. In addition, for the nine months ended September 30, 2024, net cash outflows from other debt obligations decreased by $14.6 million, primarily driven by proceeds of $25.0 million in the current period from an incremental separate term loan at our Infrastructure segment, partially offset by a $4.1 million repayment on the CGIC Unsecured Note and a $1.0 million principal payment for the partial repurchase of the 2026 Convertible Notes at our Corporate Non-Segment in the current period, and a decrease in proceeds from other debt obligations with Lancer Capital of $5.3 million at our Life Sciences segment.

### Infrastructure

#### Cash Flows

Cash flows from operating activities are the principal source of cash used to fund DBMG’s operating expenses, interest payments on debt, and capital expenditures. DBMG's short-term cash needs are primarily for working capital to support operations including receivables, inventories, and other costs incurred in performing on its contracts. DBMG attempts to structure the payment arrangements under its contracts to match costs incurred under the project. To the extent it is able to bill in advance of costs incurred, DBMG generates working capital through billings in excess of costs and recognized earnings on uncompleted contracts. DBMG relies on its credit facilities to meet its working capital needs. DBMG believes that its available funds, cash generated by operating activities and funds available under its bank credit facilities will be adequate to meet all funding requirements for its operating expenses, working capital needs, interest payments on debt and capital expenditures for the foreseeable future. However, DBMG may expand its operations through future acquisitions and may require additional equity or debt financing.

DBMG is required to make monthly interest payments on all of its debt. Based upon the September 30, 2024 debt balance, DBMG anticipates that its interest payments will be approximately $2.4 million for the fourth quarter of 2024 and approximately $1.9 million for each quarter of 2025.

### Off- Balance Sheet Arrangements

We may enter into certain off-balance sheet arrangements in the ordinary course of business. Our off-balance sheet transactions may include, but are not limited to: leases that have not yet commenced, short-term leases, liabilities associated with non-cancelable operating leases with durations of less than twelve months, letter of credit obligations, surety, performance or payment bonds entered into in the normal course of business, and liabilities associated with multi-employer pension plans. Refer to Note 9. Leases, and Note 13. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on leases and letters of credit and performance and/or payment bonds, respectively.

### New Accounting Pronouncements

For information on new accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Critical Accounting Estimates

There have been no material changes in the Company’s critical accounting policies during the period ended September 30, 2024. For information about critical accounting policies and estimates, refer to “Critical Accounting Estimates” under Item 7 of our 2023 Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 6, 2024.

### Related Party Transactions

For a discussion of our Related Party Transactions, refer to Note 16. Related Parties of our Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains or incorporates a number of "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based on current expectations, and are not strictly historical statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "believe," "anticipate," "future," "forward," "potential," "estimate," "opportunity," "goal," "objective," "growth," "outcome," "could," "expect," "intend," "plan," "strategy," "provide," "commitment," "result," "seek," "pursue," "ongoing," "include" or in the negative of such terms or comparable terminology. These forward-looking statements inherently involve certain risks and uncertainties and are not guarantees of performance, results, or the creation of stockholder value, although they are based on our current plans or assessments which we believe to be reasonable as of the date hereof.

Factors that could cause actual results, events and developments to differ include, without limitation: the ability of our subsidiaries (including, target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries’ ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing the integration of financial reporting of acquired or target businesses with INNOVATE or the applicable subsidiary of INNOVATE, completing future acquisitions and dispositions, litigation, potential and contingent liabilities, management’s plans, changes in regulations and taxes.

We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

Forward-looking statements are not guarantees of performance. You should understand that the following important factors, in addition to those discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 6, 2024 and the documents incorporated herein by reference, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements. You should also understand that many factors described under one heading below may apply to more than one section in which we have grouped them for the purpose of this presentation. As a result, you should consider all of the following factors, together with all of the other information presented herein, in evaluating our business and that of our subsidiaries.

### INNOVATE Corp. and Subsidiaries

Our actual results or other outcomes may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- the passing in 2023 of Mr. Barr, our former Chief Executive Officer, President and Director and the successful transition of his management responsibilities;
- our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations;
- our inability to continue operating as a going concern;
- the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur;
- the impact of covenants in the Indenture governing INNOVATE’s 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Unsecured Note and Revolving Line of Credit, the Certificates of Designation governing INNOVATE’s Series A-3 Preferred Stock and Series A-4 Preferred Stock and all other subsidiary debt obligations as summarized in Note 11. Debt Obligations to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 6, 2024 and future financing agreements on our ability to operate our business and finance our pursuit of acquisition opportunities;
- our possible inability to generate sufficient liquidity, margins, earnings per share, cash flow and working capital from our operating segments;
- our dependence on certain key personnel;
- bank failures or other similar events that could adversely affect our and our customers' and vendors' liquidity and financial performance;
- our possible inability to hire and retain qualified executive management, sales, technical and other personnel;
- the potential for, and our ability to, remediate future material weaknesses in our internal controls over financial reporting;
- the impact of recent supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs;
- the impact of a higher interest rate environment;
- the effects related to or resulting from military actions in the Middle East, including Israel and the Gaza Strip, and Russia's military action in Ukraine, including the imposition of additional sanctions and export controls, as well as the broader impact to financial markets and the global macroeconomic and geopolitical environment;
- increased competition in the markets in which our operating segments conduct their businesses;
- limitations on our ability to successfully identify any strategic acquisitions or business opportunities and to compete for these opportunities with others who have greater resources;
- our ability to effectively increase the size of our organization, if needed, and manage our growth;
- the impact of expending significant resources in considering acquisition targets or business opportunities that are not consummated;
- our expectations and timing with respect to our ordinary course acquisition activity and whether such acquisitions are accretive or dilutive to stockholders;
- the effect any interests our officers, directors, stockholders and their respective affiliates may have in certain transactions in which we are involved;
- uncertain global economic conditions in the markets in which our operating segments conduct their businesses;
- the impact of catastrophic events, including natural disasters, pandemic illness and the outbreak of war, or acts of terrorism;
- potential impacts on our business resulting from climate change, greenhouse gas regulations, and the impact of climate change-related changes in the frequency and severity of weather patterns;
- the impact of additional material charges associated with our oversight of acquired or target businesses and the integration of our financial reporting;
- tax consequences associated with our acquisition, holding and disposition of target companies and assets;
- our ability to remain in compliance with the listing standards of the New York Stock Exchange;
- the Reverse Stock Split may not result in a sustained increase in the per share price of our common stock;
- the ability of our operating segments to attract and retain customers;
- our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending;
- management’s plans, goals, forecasts, expectations, guidance, objectives, strategies and timing for future operations, acquisitions, synergies, asset dispositions, fixed asset and goodwill impairment charges, tax and withholding expense, selling, general and administrative expenses, product plans, performance and results;
- management’s assessment of market factors and competitive developments, including pricing actions and regulatory rulings;
- our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, including the shut-down of our Network business by our Spectrum segment, that we may make in the future and the effect of any such dispositions or sales on our results of operations;
- the possibility of indemnification claims arising out of divestitures of businesses; and
- our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all.

### Infrastructure / DBM Global Inc.

Our actual results or other outcomes of DBMG, and, thus, our Infrastructure segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- adverse impacts from weather affecting DBMG’s performance and timeliness of completion of projects, which could lead to increased costs and affect the quality, costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- cost overruns on fixed-price or similar contracts or failure to receive timely or proper payments on cost-reimbursable contracts, whether as a result of improper estimates, performance, disputes, or otherwise;
- uncertain timing and funding of new contract awards, as well as project cancellations;
- potential impediments and limitations on our ability to complete ordinary course acquisitions in anticipated time frames or at all;
- changes in the costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- the impact of inflationary pressures;
- adverse outcomes of pending claims or litigation or the possibility of new claims or litigation, and the potential effect of such claims or litigation on DBMG’s business, financial condition, results of operations or cash flow;
- risks associated with labor productivity, including performance of subcontractors that DBMG hires to complete projects;
- its ability to realize cost savings from expected performance of contracts, whether as a result of improper estimates, performance, or otherwise;
- its ability to settle or negotiate unapproved change orders and claims;
- fluctuating revenue resulting from a number of factors, including the cyclical nature of the individual markets in which our customers operate;
- our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; and
- lack of necessary liquidity to provide bid, performance, advance payment and retention bonds, guarantees, or letters of credit securing DBMG’s obligations under bids and contracts or to finance expenditures prior to the receipt of payment for the performance of contracts.

### Life Sciences / Pansend Life Sciences, LLC

Our actual results or other outcomes of Pansend Life Sciences, LLC, and, thus, our Life Sciences segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our Life Sciences segment’s ability to invest in development stage companies;
- our Life Sciences segment’s ability to develop products and treatments related to its portfolio companies;
- medical advances in healthcare and biotechnology;
- governmental regulation in the healthcare industry; and
- our Life Science's segment possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all.

### Spectrum / HC2 Broadcasting Holdings Inc.

Our actual results or other outcomes of Broadcasting, and, thus, our Spectrum segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our Spectrum segment’s ability to operate in highly competitive markets and maintain market share;
- our Spectrum segment’s ability to effectively implement its business strategy or be successful in the operation of its business;
- our Spectrum segment's possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all;
- new and growing sources of competition in the broadcasting industry; and
- FCC regulation of the television broadcasting industry.

We caution the reader that undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this document. Neither we nor any of our subsidiaries undertake any duty or responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this document or to reflect actual outcomes, except as required by applicable law.

## Controls and procedures

As filed, 2,206 characters.

### Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2024, our disclosure controls and procedures were effective. Disclosure controls and procedures mean our controls and other procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2024, one of our subsidiaries successfully implemented a new Enterprise Resource Planning ("ERP") system, which replaced operating and financial systems and resulted in changes to our internal controls over financial reporting. We have taken steps to ensure that appropriate controls are in place and operating effectively in the new system environment. These changes have been and will continue to be subject to our evaluation of the operating effectiveness of internal controls over financial reporting.

Other than as disclosed above, there have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,407 characters.

Except as set forth below, there have been no material changes in our risk factors from those disclosed in Part 1, Item 1A of our Fiscal Year 2023 Form 10-K, which was filed with the SEC on March 6, 2024. See "Risk Factors" in Item 1A of Part I of such Fiscal Year 2023 Form 10-K for a complete description of the material risks we face.

### Substantial doubt about our ability to continue as a going concern

As of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The principal conditions leading to this conclusion are the upcoming maturities of current debt at certain of the Company's subsidiaries as well as from certain cross-default provisions in the Company's Senior Secured Notes. Based on these conditions, the Company may not be able to meet its obligations at maturity and comply with certain cross-default provisions under the Senior Secured Notes over the next 12 months. The Company plans to alleviate these conditions through various initiatives it is currently exploring, including refinancing the debt at Broadcasting and DBMG, pursuing asset sales, and raising additional capital. However, there can be no assurance that the Company will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance its existing debt, on attractive terms, or at all, nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with the Company’s debt covenants or other possible events of default. Further, there can be no assurance that the Company will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern. The inability to refinance or extend the maturity of the current debt at the Company's subsidiaries, or to raise sufficient cash to pay the debt at maturity would have a material adverse effect on our financial condition and likely cause the price of the Company’s common stock to decline.

Filed Nov 6, 2024.
Source: SEC EDGAR, the filing index for accession 0001006837-24-000155. Last ingested by Listed: Nov 14, 2026, 23:42 ET. No prices; not investment advice.
